Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Home/Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Pharmaceutical Manufacturing, Pharmacy, Drug Pipeline, Pharma & Healthcare

Publication ID:

GBI0418004

Publication Date:

April 30, 2018

Pages:

Publisher:

GBI Research

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for RSV and HPIV-3 infections, and features dormant and discontinued products.

RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat.

Scope

- Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 GBI Research Report Coverage 8
2.2 Respiratory Syncytial Virus (RSV) Infections – Overview 8
2.3 Human Parainfluenza Virus 3 Infections – Overview 8
3 Therapeutics Development 9
3.1 Respiratory Syncytial Virus (RSV) Infections 9
3.2 Human Parainfluenza Virus 3 Infections 22
4 Therapeutics Assessment 25
4.1 Respiratory Syncytial Virus (RSV) Infections 25
4.2 Human Parainfluenza Virus 3 Infections 31
5 Companies Involved in Therapeutics Development 38
5.1 Respiratory Syncytial Virus (RSV) Infections 38
5.2 Human Parainfluenza Virus 3 Infections 61
6 Dormant Projects 63
6.1 Respiratory Syncytial Virus (RSV) Infections 63
6.2 Human Parainfluenza Virus 3 Infections 67
7 Discontinued Products 68
7.1 Respiratory Syncytial Virus (RSV) Infections 68
7.2 Human Parainfluenza Virus 3 Infections 68
8 Product Development Milestones 69
8.1 Respiratory Syncytial Virus (RSV) Infections 69
9 Appendix 81
9.1 Methodology 81
9.2 Coverage 81
9.3 Secondary Research 81
9.4 Primary Research 81
9.5 Expert Panel Validation 81
9.6 Contact Us 82
9.7 Disclaimer 82

List of Tables
1.1 List of Tables
Table 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Table 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 11
Table 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 14
Table 4: Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 15
Table 5: Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 20
Table 6: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Table 7: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Table 8: Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 9: Products under Development by Companies, Human Parainfluenza Virus 3 Infections 24
Table 10: Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 11: Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections 26
Table 12: Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections 27
Table 13: Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections 29
Table 14: Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections 31
Table 15: Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections 32
Table 16: Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections 34
Table 17: Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections 36
Table 18: Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections 37
Table 19: Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc, 38
Table 20: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA 38
Table 21: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV 39
Table 22: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc 39
Table 23: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc 40
Table 24: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc 40
Table 25: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd 41
Table 26: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC 41
Table 27: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc 41
Table 28: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc 42
Table 29: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S 43
Table 30: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc 43
Table 31: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG 44
Table 32: Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA 44
Table 33: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc 45
Table 34: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc 45
Table 35: Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd 46
Table 36: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd 46
Table 37: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc 47
Table 38: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc 47
Table 39: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc 48
Table 40: Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc 48
Table 41: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc 49
Table 42: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc 49
Table 43: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc 50
Table 44: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson 51
Table 45: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc 51
Table 46: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc 52
Table 47: Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA 52
Table 48: Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC 52
Table 49: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB 53
Table 50: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp 54
Table 51: Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp 54
Table 52: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc 54
Table 53: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc 55
Table 54: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc 55
Table 55: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc 56
Table 56: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd 56
Table 57: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd 57
Table 58: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC 57
Table 59: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd 58
Table 60: Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc 58
Table 61: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH 58
Table 62: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc 59
Table 63: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc 59
Table 64: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG 60
Table 65: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc 60
Table 66: Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc 60
Table 67: Human Parainfluenza Virus 3 Infections – Pipeline by 3-V Biosciences Inc 61
Table 68: Human Parainfluenza Virus 3 Infections – Pipeline by Amarillo Biosciences Inc 61
Table 69: Human Parainfluenza Virus 3 Infections – Pipeline by Ansun Biopharma Inc 62
Table 70: Human Parainfluenza Virus 3 Infections – Pipeline by Moderna Therapeutics Inc 62
Table 71: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects 63
Table 72: Human Parainfluenza Virus 3 Infections – Dormant Projects 67
Table 73: Respiratory Syncytial Virus (RSV) Infections – Discontinued Products 68
Table 74: Human Parainfluenza Virus 3 Infections – Discontinued Products 68

List of Figures
1.2 List of Figures
Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Figure 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 10
Figure 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 13
Figure 4: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Figure 5: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Figure 6: Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 7: Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 8: Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 26
Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 27
Figure 10: Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 11: Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 12: Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 29
Figure 13: Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 30
Figure 14: Number of Products by Targets, Human Parainfluenza Virus 3 Infections 31
Figure 15: Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections 32
Figure 16: Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 17: Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 18: Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 19: Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 20: Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections 36
Figure 21: Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections 37

Companies Covered

3-V Biosciences Inc
Abivax SA
Ablynx NV
ADMA Biologics Inc
Agilvax Inc
Amarillo Biosciences Inc
Anima Biotech Ltd
Ansun Biopharma Inc
Aridis Pharmaceuticals LLC
Artificial Cell Technologies Inc
AstraZeneca Plc
Bavarian Nordic A/S
Celltrion Inc
Curevac AG
DBV Technologies SA
Enanta Pharmaceuticals Inc
Evec Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
GenVec Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Human Parainfluenza Virus 3 Infections
iBio Inc
Immunovaccine Inc
Immunwork Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
Kineta Inc
mAbxience SA
MedImmune LLC
Medivir AB
Mymetics Corp
NanoBio Corp
Navigen Inc
Novavax Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Pulmocide Ltd
ReViral Ltd
Romark Laboratories LC
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Themis Bioscience GmbH
Vault Pharma Inc
Vaxart Inc
Virometix AG
Visterra Inc
VLP Biotech Inc

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".